Investors cheering Syros: RARα agonist to phase II in AML, MDS with $40M
A gene control pathway mapper working directly in human disease tissue, Syros Pharmaceuticals Inc. pulled down $40 million by way of its preferred stock transaction to advance SY-1425 (tamibarotene), described as a first-in-class selective agonist to retinoic acid receptor alpha (RARα), into a phase II trial.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST